Meagan Montesion

22PUBLICATIONS
165CO-AUTHORS
Molecular targetsPredictive and prognostic markersTumour immunologyCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (22)

|May 13, 2025
Nivolumab plus low-dose ipilimumab in hypermutated HER2-negative metastatic breast cancer: a phase II trial (NIMBUS).

Romualdo Barroso-Sousa, Jorge Gomez Tejeda Zanudo, Tianyu Li

|Feb 27, 2025
Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.

Ferdinandos Skoulidis, Haniel A Araujo, Minh Truong Do

|Oct 09, 2024
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.

Ferdinandos Skoulidis, Haniel A Araujo, Minh Truong Do

|Jul 22, 2024
Intratumoral Escherichia Is Associated With Improved Survival to Single-Agent Immune Checkpoint Inhibition in Patients With Advanced Non-Small-Cell Lung Cancer.

Arielle Elkrief, Meagan Montesion, Smruthy Sivakumar

Pageof 4